Research
Hormonal
Metformin is marginally cost-saving compared to placebo over 10 years in high-risk adults, with slightly lower costs and nearly the same QALYs as placebo.
For high-risk individuals, metformin is a cost-saving option compared to no intervention, with slightly lower total medical costs and similar quality-adjusted life years over 10 years.
StrongSupportsVERY_HIGH confidence
metformin had slightly lower costs and nearly the same QALYs as placebo... metformin is marginally cost-saving or at least cost-neutral compared with placebo.
Why this rating
Large-scale, randomized controlled trial (DPP/DPPOS) with 10-year follow-up.
Source
The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group · Diabetes Care · 2012
DOI 10.2337/dc11-1468
rct · n=3234Cited 429×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →